topic:"Neoplasms - drug therapy" found 97 records - Provincial Hospitals Library Catalogue

Advances in DNA repair in cancer therapy

https://libcat.nshealth.ca/en/permalink/provcat32399

Lawrence Panasci, Raquel Aloyz, Moulay Alaoui-Jamali, editors. --New York, NY: Springer , c2013.

Available Online: View e-Book

Location: Online

This book deals with the emerging role of various DNA repair proteins and the regulatory elements which are implicated in cancer therapy such as DNA cross-linking agents, radiotherapy and bleomycin. The DNA repair genes discussed include those involved in BRCA/Rad51-related homologous recombinational repair, DNA-PK related nonhomologous endjoining and the nucleotide excision repair gene, ERCC1. Moreover, the role of regulatory genes such as PARP, ATR, telomerase, growth factor receptors and dow…

Available Online: View e-Book

Other Authors: Panasci, Lawrence; Aloyz, Raquel; Alaoui-Jamali, Moulay

Responsibility: Lawrence Panasci, Raquel Aloyz, Moulay Alaoui-Jamali, editors

Place of Publication: New York, NY

Publisher: Springer

Date of Publication: c2013

Physical Description: 1 online resource (viii, 312 p. : 35 ill., 25 ill. in color)

Series Vol.: 72

Series Title: Cancer drug discovery and development

ISBN: 9781461447412

Subjects (MeSH): Antineoplastic Agents - therapeutic use; DNA Repair; Neoplasms - drug therapy; Neoplasms - genetics

Subjects (LCSH): Oncology

Abstract: This book deals with the emerging role of various DNA repair proteins and the regulatory elements which are implicated in cancer therapy such as DNA cross-linking agents, radiotherapy and bleomycin. The DNA repair genes discussed include those involved in BRCA/Rad51-related homologous recombinational repair, DNA-PK related nonhomologous endjoining and the nucleotide excision repair gene, ERCC1. Moreover, the role of regulatory genes such as PARP, ATR, telomerase, growth factor receptors and downstream kinase signalling is examined.

Contents: Repair of DNA interstrand cross-links produced by cancer chemotherapeutic drugs -- DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy -- Growth factor receptor signaling, DNA damage response, and cancer cell susceptibility to chemotherapy and relapses -- Relationship between DNA-repair genes, cellular radiosensitivity, and the response of tumors annd normal tissues to radiotherapy -- Important roles of ERCCI in DNA repair and targeted therapy -- The role of BRCA1 and BRCA2 in anticancer drug therepy -- DNA-PK in CLL chemotherapy -- Poly (ADP) ribose polymerase at the interface of DNA damage signaling and DNA repair -- Cellular protection against the antitumor drug bleomycin -- ATR as a therapeutic target -- Telomores, Telomerase, and DNA damage response in cancer therapy -- RAD51 is a key protein of DNA repair and homologous recombination in humans -- Index.

Format: e-Book

Location: Online

Advances in peritoneal surface oncology

https://libcat.nshealth.ca/en/permalink/provcat30092

--Berlin, Heidelberg: Springer-Verlag , c2007.

Available Online: View e-Book

Location: Online

Available Online: View e-Book

Other Authors: González-Moreno, Santiago

Place of Publication: Berlin, Heidelberg

Publisher: Springer-Verlag

Date of Publication: c2007

Series Vol.: 169

Series Title: Resent results in cancer research

ISBN: 9783540307600

Subjects (MeSH): Carcinoma - therapy; Mesothelioma - therapy; Peritoneal Neoplasms - drug therapy; Peritoneal Neoplasms - surgery

Subjects (LCSH): Oncology; Abdomen - Surgery

Format: e-Book

Location: Online

Angiogenesis inhibition

https://libcat.nshealth.ca/en/permalink/provcat28492

--Berlin, Heidelberg: Springer-Verlag , c2010.

Available Online: View e-Book

Location: Online

Available Online: View e-Book

Other Authors: Liersch, Rüdiger; Berdel, Wolfgang E; Kessler, Torsten

Place of Publication: Berlin, Heidelberg

Publisher: Springer-Verlag

Date of Publication: c2010

Series Vol.: 180

Series Title: Recent results in cancer research

ISBN: 9783540782810

Subjects (MeSH): Angiogenesis Inhibitors; Neoplasms - drug therapy; Neovascularization, pathologic - drug therapy

Subjects (LCSH): Oncology; Hematology

Format: e-Book

Location: Online

Antiangiogenic Agents in Cancer Therapy

https://libcat.nshealth.ca/en/permalink/provcat40632

edited by Beverly A. Teicher, Lee M. Ellis. (2nd ed.) --Totowa, NJ: Humana Press , c2008.

Available Online: View e-Book

Location: Online

Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art…

Available Online: View e-Book

Other Authors: Teicher, Beverly A; Ellis, Lee M

Responsibility: edited by Beverly A. Teicher, Lee M. Ellis

Edition: 2nd ed.

Place of Publication: Totowa, NJ

Publisher: Humana Press

Date of Publication: c2008

Physical Description: 1 online resource (xviii, 559 p. : ill.)

Series Title: Cancer drug discovery and development

ISBN: 9781597451840; 9781588298706 (print ed.)

Subjects (MeSH): Angiogenesis Inhibitors - therapeutic use; Antineoplastic Agents - therapeutic use; Neoplasms - drug therapy; Neovascularization, pathologic - drug therapy

Abstract: Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art of angiogenesis and therapy with a compendium of scientific findings and approaches to the study of angiogenesis in cancer. Leaders in the field present chapters on such topics as the environmental influences and the genetic and physiologic abnormalities that mediate angiogenesis and its role in the progression of malignant disease, working models of tumor angiogenesis, and the role of angiogenesis inhibition in the therapy of malignant disease in humans. Comprehensive and cutting-edge, Antiangiogenic Agents in Cancer Therapy, Second Edition is an ideal, valuable guide to the most recent advances in the field, and a collection that will be useful for many years to come.

Contents: Part I. Basic Biology of Angiogenesis -- Vascular Endothelial Growth Factor Family and Its Receptors -- The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors -- The Role of Integrins in Tumor Angiogenesis -- Tumor Endothelial Cell Abnormalities -- The Extracellular Matrix and VEGF Processing -- Endothelial Precursor Cells -- Role of Pericytes in Angiogenesis -- Newer Vascular Targets -- Chemokines in Angiogenesis -- Angiopoietin/Tie2 Signaling Regulates Tumor Angiogenesis -- Imaging Angiogenesis -- Tumor Blood Vessels -- Lymphatic System in the Pathology of Cancer -- Part II. Translational Research in Tumor Angiogenesis -- VEGF in the Adult -- Normalization of Tumor Vasculature and Microenvironment -- Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice and Man -- Small-Molecule Vascular Disrupting Agents in Cancer Therapy -- Normalization of Tumor Vasculature and Improvement of Radiation Response by Antiangiogenic Agents -- Challenges in Translating Antiangiogenic Therapy from the Bench to Bedside -- Regulation of Angiogenesis in Cancer and Its Therapeutic Implications -- Part III. Antiangiogenic Therapy in the Clinical Trial Results and Future Directions -- Angiogenesis and Angiogenesis Inhibition in Sarcomas -- Antiangiogenesis Agents in Colorectal Cancer -- Antiangiogenic Therapy for Primary CNS Tumors -- Angiogenesis Inhibitors for the Treatment of Lung Cancer -- Antiangiogenic Therapy of Renal Cell Carcinoma -- Antiangiogenesis Therapies in Gynecologic Malignancies -- Antiangiogenic Agents in Myeloid Malignancies -- Angiogenesis in Malignant and Non-Malignant Pediatric Tumors -- Prognostic and Predictive Significance of Surrogate Biomarkers of Angiogenesis -- Endpoints for the Determination of Efficacy of Antiangiogenic Agents in Clinical Trials -- The Role of Imaging in the Clinical Development of Antiangiogenic Agents.

Format: e-Book

Location: Online

Antibody-drug conjugates and immunotoxins : from pre-clinical development to therapeutic applications

https://libcat.nshealth.ca/en/permalink/provcat32428

Gail Lewis Phillips, editor. --New York, NY: Springer , c2013.

Available Online: View e-Book

Location: Online

The concept of delivering 'magic bullets' to treat diseases was first proposed by Paul Erlich in the early 1900's. The realization of this concept for the treatment of cancer occurred in the late 1990's with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under int…

Available Online: View e-Book

Other Authors: Phillips, Gail Lewis

Responsibility: Gail Lewis Phillips, editor

Place of Publication: New York, NY

Publisher: Springer

Date of Publication: c2013

Physical Description: 1 online resource (ix, 372 p. : 88 ill., 45 ill. in color)

Series Title: Cancer drug discovery and development

ISBN: 9781461454564

Subjects (MeSH): Antibodies; Drug Combinations; Immunotoxins - therapeutic use; Neoplasms - drug therapy

Subjects (LCSH): Oncology; Monoclonal antibodies

Abstract: The concept of delivering 'magic bullets' to treat diseases was first proposed by Paul Erlich in the early 1900's. The realization of this concept for the treatment of cancer occurred in the late 1990's with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics. More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use. This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer.

Contents: Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins -- Antibody-Drug Conjugate Development -- Components of ADC Development: Assay Methodologies and Challenges -- Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates -- Predictive Biomarkers for Antibody-Drug Conjugates -- Factors Involved in the Design of Cytotoxic Payloads for Antibody-Drug Conjugates -- Linker Technology and Impact of Linker Design on ADC Properties -- Antibody-drug conjugates for the treatment of B-cell malignancies -- Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies -- Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies -- Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer -- CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE) -- Case Study: An Antibody-Drug Conjugate Targeting MUC16 for Ovarian Cancer -- EphA2 Immunoconjugate -- Anti-PSMA Antibody-Drug Conjugates -- Targeting CD56 (NCAM)-expressing Neoplasms with Lorvotuzumab Mertansine -- Studies on the Metabolism of Antibody-Drug Conjugates -- Design, Development and Characterization of Recombinant Immunotoxins Targeting HER2/neu -- The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors -- Index

Format: e-Book

Location: Online

Apoptosis, Senescence, and Cancer

https://libcat.nshealth.ca/en/permalink/provcat29394

edited by David A. Gewirtz, Shawn E. Holt, Steven Grant. (2nd ed.) --Totowa, NJ: Humana Press , c2007.

Available Online: View e-Book

Location: Online

Available Online: View e-Book

Author: Gewirtz, David A

Other Authors: Holt, Shawn E; Grant, Steven

Responsibility: edited by David A. Gewirtz, Shawn E. Holt, Steven Grant

Edition: 2nd ed.

Place of Publication: Totowa, NJ

Publisher: Humana Press

Date of Publication: c2007

Series Title: Cancer drug discovery and development

ISBN: 9781597452212

Subjects (MeSH): Apoptosis; Cell Aging - drug effects; Cell Transformation, Neoplastic; Neoplasms - drug therapy

Subjects (LCSH): Oncology; Cytology

Format: e-Book

Location: Online

Camptothecins in Cancer Therapy

https://libcat.nshealth.ca/en/permalink/provcat28891

edited by Val R. Adams, Thomas G. Burke. --Totowa, NJ: Humana Press , c2005.

Available Online: View e-Book

Location: Online

Available Online: View e-Book

Author: Adams, Val R

Other Authors: Burke, Thomas G

Responsibility: edited by Val R. Adams, Thomas G. Burke

Place of Publication: Totowa, NJ

Publisher: Humana Press

Date of Publication: c2005

Series Title: Cancer drug discovery and development

ISBN: 9781592598663

Subjects (MeSH): Camptothecin - pharmacology; Camptothecin - therapeutic use; Neoplasms - drug therapy; Antineoplastic Agents, Phytogenic - therapeutic use

Subjects (LCSH): Oncology; Pharmacy

Format: e-Book

Location: Online

Cancer Chemotherapy in Clinical Practice

https://libcat.nshealth.ca/en/permalink/provcat30817

Terry Priestman. (2nd ed.) --London: Springer , c2012.

Available Online: View e-Book

Location: Online

The last decade has seen many dramatic changes in cancer chemotherapy, with the introduction of a number of new forms of treatment as well as important developments in the more traditional fields of cytotoxic and hormonal therapy. Now in its second edition, this book summarizes the whole range of systemic cancer therapies and their clinical applications, taking into account new drugs and the emerging concept of personalized therapy. Intended as an introductory text for junior doctors, nurses a…

Available Online: View e-Book

Author: Priestman, Terrence

Responsibility: Terry Priestman

Edition: 2nd ed.

Place of Publication: London

Publisher: Springer

Date of Publication: c2012

Physical Description: 1 online resource (xiii, 177 p. : 15 ill., 3 ill. in color)

ISBN: 9780857297273

Subjects (MeSH): Neoplasms - drug therapy; Antineoplastic Agents - therapeutic use

Subjects (LCSH): Oncology; Pharmacy

Abstract: The last decade has seen many dramatic changes in cancer chemotherapy, with the introduction of a number of new forms of treatment as well as important developments in the more traditional fields of cytotoxic and hormonal therapy. Now in its second edition, this book summarizes the whole range of systemic cancer therapies and their clinical applications, taking into account new drugs and the emerging concept of personalized therapy. Intended as an introductory text for junior doctors, nurses and medical students, Cancer Chemotherapy in Clinical Practice is divided into three sections: The Theoretical Basis of Cancer Chemotherapy: following a historical introduction the different treatment modalities are explained in the context of basic tumor biology Practical Aspects of Chemotherapy: covering dosing and drug delivery together with an extensive discussion of possible side-effects and their management Chemotherapy in the Management of Cancer: explaining the place of drug treatment and the outcomes that can be expected from chemotherapy in all the major cancers.

Contents: 1. The Theoretical Basis of Cancer Chemotherapy -- 2. Practical aspects of chemotherapy -- 3. Part III: Chemotherapy in the management of cancer

Format: e-Book

Location: Online

Cancer Management in Man : Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures

https://libcat.nshealth.ca/en/permalink/provcat28897

edited by Boris R. Minev. --Dordrecht ; New York: Springer Science+Business Media , c2011.

Available Online: View e-Book

Location: Online

Available Online: View e-Book

Author: Minev, Boris R

Responsibility: edited by Boris R. Minev

Place of Publication: Dordrecht ; New York

Publisher: Springer Science+Business Media

Date of Publication: c2011

Series Vol.: 13

Series Title: Cancer growth and progression

ISBN: 9789048197040

Subjects (MeSH): Antineoplastic Agents - therapeutic use; Neoplasms - drug therapy; Neoplasms - therapy

Subjects (LCSH): Oncology

Format: e-Book

Location: Online

Cancer treatment and the ovary : clinical and laboratory analysis of ovarian toxicity

https://libcat.nshealth.ca/en/permalink/provcat38860

edited by Richard A. Anderson, Norah Spears. --London, UK: Elsevier , c2015.

Available Online: View e-Book

Access: Registration required for PDF access.

Location: Online

Available Online: View e-Book

Other Authors: Anderson, Richard A

Responsibility: edited by Richard A. Anderson, Norah Spears

Alternate Title: Cancer treatment & the ovary

Place of Publication: London, UK

Publisher: Elsevier

Date of Publication: c2015

Physical Description: 1 online resource, 149 p.

ISBN: 9780128015919

Subjects (MeSH): Neoplasms - drug therapy; Ovary - drug effects

Access: Registration required for PDF access.

Format: e-Book

Location: Online

Cancer treatment and the ovary : clinical and laboratory analysis of ovarian toxicity

https://libcat.nshealth.ca/en/permalink/provcat50457

Anderson, Richard. (1st ed.) --Philadelphia, PA: Elsevier , 2015.

Available Online: View e-Book

Location: Online

Available Online: View e-Book

Author: Anderson, Richard

Edition: 1st ed.

Place of Publication: Philadelphia, PA

Publisher: Elsevier

Date of Publication: 2015

ISBN: 9780128015919

Subjects (MeSH): Neoplasms - drug therapy; Ovary - drug effects

Notes: Access to this online resource is restricted to IWK Health Centre employees working from inside the hospital network.

Format: e-Book

Location: Online

Cardio-Oncology : The Clinical Overlap of Cancer and Heart Disease

https://libcat.nshealth.ca/en/permalink/provcat41453

Gretchen G. Kimmick, Daniel J. Lenihan, Douglas B. Sawyer, Erica L. Mayer, Dawn L. Hershman, editors. --Cham: Springer , 2017.

Available Online: View e-Book

Location: Online

Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics: Cardiac complications in patients receiving cancer therapy; The treatment of cancer in patients with cardiovascular disease; The treatment of cardiovascular disease in patients with cancer. When relevant to medical practice, epidemiology and basic science are also included in the discussion and each chapter is written by an oncologist a…

Available Online: View e-Book

Other Authors: Kimmick, Gretchen G; Lenihan, Daniel J; Sawyer, Douglas B; Mayer, Erica L; Hershman, Dawn L

Responsibility: Gretchen G. Kimmick, Daniel J. Lenihan, Douglas B. Sawyer, Erica L. Mayer, Dawn L. Hershman, editors

Place of Publication: Cham

Publisher: Springer

Date of Publication: 2017

Physical Description: 1 online resource (xv, 319 pages) : 55 illus., 49 illus. in color

ISBN: 9783319430966; 9783319430942 (print ed.)

Subjects (MeSH): Antineoplastic Agents - adverse effects; Cardiotoxicity - complications; Cardiovascular Diseases - complications; Cardiovascular Diseases - prevention & control; Neoplasms - complications; Neoplasms - drug therapy

Abstract: Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics: Cardiac complications in patients receiving cancer therapy; The treatment of cancer in patients with cardiovascular disease; The treatment of cardiovascular disease in patients with cancer. When relevant to medical practice, epidemiology and basic science are also included in the discussion and each chapter is written by an oncologist and a cardiologist. Additionally, the chapters follow a similar format to make the book truly interdisciplinary, user-friendly, and clinically applicable to specialists and non-specialists who care for patients with both cancer and cardiovascular disease.

Contents: 1. Epidemiology of Cardio-Oncology -- 2. Cardiotoxicity of Anticancer Therapies -- 3. Screening and Monitoring for Cardiotoxicity During Cancer Treatment -- 4. Management of Chemotherapy-Associated Cardiomyopathy -- 5. Treatment of Hypertension in Patients Receiving Cancer Therapy -- 6. Preoperative and Pre-transplant Cardiac Evaluation in the Cancer Patient -- 7. Radiation Therapy and Cardiotoxicity -- 8. Management of Patients with Coronary Disease and Cancer: Interactions Between Cancer, Cancer Treatment, and Ischemia -- 9. Vascular Complications of Cancer and Cancer Therapy -- 10. Breast Cancer Cardio-Oncology -- 11. Cardiac Toxic Chemotherapy and Cancer Survivorship -- 12. Geriatric Cardio-oncology -- 13. Future Clinical and Professional Directions in Cardio-oncology.

Format: e-Book

Location: Online

Checkpoint Controls and Targets in Cancer Therapy

https://libcat.nshealth.ca/en/permalink/provcat29742

edited by Zahid H. Siddik. --Totowa, NJ: Humana Press , c2009.

Available Online: View e-Book

Location: Online

Available Online: View e-Book

Author: Siddik, Zahid H

Responsibility: edited by Zahid H. Siddik

Place of Publication: Totowa, NJ

Publisher: Humana Press

Date of Publication: c2009

Series Title: Cancer drug discovery and development

ISBN: 9781607611783

Subjects (MeSH): Antineoplastic Agents - pharmacology; Cell Cycle Checkpoints; Cell Cycle - drug effects; Neoplasms - drug therapy

Format: e-Book

Location: Online

Chemotherapy and biotherapy guidelines and recommendations for practice

https://libcat.nshealth.ca/en/permalink/provcat40858

Polovich, Martha. Oncology Nursing Society. --Pittsburgh, PA: Oncology Nursing Society , c2014.

Available Online: View e-Book

Location: Online

Available Online: View e-Book

Author: Polovich, Martha

Corporate Author: Oncology Nursing Society

Other Authors: Olsen, MiKaela M.; LeFebvre, Kristine B.

Place of Publication: Pittsburgh, PA

Publisher: Oncology Nursing Society

Date of Publication: c2014

Physical Description: 473 p.

ISBN: 9781935864332

Subjects (MeSH): Neoplasms - drug therapy - Outlines; Neoplasms - drug therapy - Practice Guideline

Format: e-Book

Location: Online

Chemotherapy and Immunotherapy in Urologic Oncology : A Guide for the Advanced Practice Provider

https://libcat.nshealth.ca/en/permalink/provcat46364

Edouard J. Trabulsi, Costas D. Lallas, Anne E. Lizardi-Calvaresi, editors. --Cham: Springer , c2021.

Available Online: View e-Book

Access: NEW Springer 2021

Location: Online

This book is designed to familiarize clinical practitioners in systemic therapy options and medical management of urologic malignancies including prostate cancer, bladder and upper tract urothelial carcinoma, and renal cell carcinoma. Organized by organ system, the text highlights new therapies such as novel forms of androgen deprivation, cytotoxic chemotherapy, immune check point and immunomodulatory agents, and targeted therapies. Written by experts in the field, the book also reviews current…

Available Online: View e-Book

Other Authors: Trabulsi, Edouard J.; Lallas, Costas D.; Lizardi-Calvaresi, Anne E.

Responsibility: Edouard J. Trabulsi, Costas D. Lallas, Anne E. Lizardi-Calvaresi, editors

Place of Publication: Cham

Publisher: Springer

Date of Publication: c2021

Physical Description: 1 online resource (xiv, 307 p.) : 22 illus., 19 illus. in color

ISBN: 9783030520212; 9783030520205 (Print ed.); 9783030520229 (Print ed.)

Subjects (MeSH): Antineoplastic Agents - therapeutic use; Urologic Neoplasms - drug therapy; Immunotherapy - methods

Specialty: Medical Oncology; Pharmacology; Regenerative Medicine; Urology

Abstract: This book is designed to familiarize clinical practitioners in systemic therapy options and medical management of urologic malignancies including prostate cancer, bladder and upper tract urothelial carcinoma, and renal cell carcinoma. Organized by organ system, the text highlights new therapies such as novel forms of androgen deprivation, cytotoxic chemotherapy, immune check point and immunomodulatory agents, and targeted therapies. Written by experts in the field, the book also reviews current chemotherapy and immunotherapy regimens for genitourinary malignancies and discusses indications, outcomes, and toxicities, as well as clinical trial concepts. Each of the book’s chapters offers a bulleted box of clinical pearls on the particular role of the APP. Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider is a resource for urologists, uro-radiologists, medical clinicians and family practitioners alike, familiarizing its audiences with systemic therapy regimens for urologic malignancies, as well as their expected outcomes and side effects. .

Contents: Introduction: Integration of APP into Urologic Oncology Practice -- Part I. Prostate Cancer -- Overview and Active Surveillance of Prostate Cancer -- Monitoring and Managing Men Following Initial Treatment of Prostate Cancer -- Radical Prostatectomy and Survivorship after Radical Prostatectomy -- Multimodal Treatment Plans in Prostate Cancer -- Radiotherapy for Prostate Cancer -- Androgen Deprivation Treatment -- Second Generation Androgen Targeted Agents -- Chemotherapy and prostate cancer -- Radiopharmaceuticals for Prostate Cancer -- Immunotherapy and Novel Agents on the Horizon for the Treatment of Prostate Cancer -- Part II. Bladder Cancer -- Bladder Cancer: Overview, Epidemiology, Initial Presentation and Diagnosis -- Intravesical Therapy for Non Muscle Invasive Urothelial Carcinoma -- Bladder Cancer: Muscle Invasive Disease, Neoadjuvant Chemotherapy, and Radical Cystectomy -- Chemoradiation Bladder Preservation -- Metastatic Bladder Cancer and the Use of Cisplatin Chemotherapy -- Immunotherapy for Metastatic Urothelial Cancer -- Novel and experimental Strategies in the Treatment of Metastatic Urothelial Carcinoma -- Upper Tract Urothelial Carcinoma -- Part III. Kidney Cancer -- Kidney Cancer and Its Treatment -- Targeted Therapies for Treatment of Metastatic Renal Cell Carcinoma -- Immune Therapies for Metastatic Kidney Cancer -- Novel Therapies for Renal Cell Carcinoma -- Part IV. Other Malignancies -- Testicular Cancer -- Penile Cancer.

Access: NEW Springer 2021

Format: e-Book

Location: Online

Chemotherapy in Neonates and Infants : Pharmacological Oncology for Children Under 1 Year Old

https://libcat.nshealth.ca/en/permalink/provcat42571

Carolina Witchmichen Penteado Schmidt. --Cham: Springer , c2018.

Available Online: View e-Book

Location: Online

This book provides a comprehensive overview of pediatric oncology, discussing drug therapy and treatment in children under the age of 1 year. It is the first volume to focus on chemotherapy in newborns and infants, especially the daily clinical practice and treatment protocols. Intended as a practical manual, it addresses all the major topics related to pediatric oncology in an accessible and easy-to-use format. It examines topics in pediatric oncology therapeutics, including drug metabolism, e…

Available Online: View e-Book

Author: Penteado Schmidt, Carolina Witchmichen

Responsibility: Carolina Witchmichen Penteado Schmidt

Place of Publication: Cham

Publisher: Springer

Date of Publication: c2018

Physical Description: 1 online resource (xix, 198 p.) : 8 illus. in color

ISBN: 9783319705910; 9783319705903 (print ed.); 9783319705927 (print ed.)

Subjects (MeSH): Antineoplastic Agents - pharmacology; Drug-Related Side Effects and Adverse Reactions - prevention & control; Infant; Infant, Newborn; Neoplasms - drug therapy

Specialty: Medical Oncology; Pediatrics; Pharmacology

Abstract: This book provides a comprehensive overview of pediatric oncology, discussing drug therapy and treatment in children under the age of 1 year. It is the first volume to focus on chemotherapy in newborns and infants, especially the daily clinical practice and treatment protocols. Intended as a practical manual, it addresses all the major topics related to pediatric oncology in an accessible and easy-to-use format. It examines topics in pediatric oncology therapeutics, including drug metabolism, excretion, toxicity, drugs that can be used for each week or month of the patient's life, dose adjustment and treatment protocols. Chemotherapy in Neonates and Infants focuses on the safe treatment of children in the first year of life, and is aimed at pediatric oncology/hematology institutions, clinics and departments. It is particularly valuable for researchers, pediatric oncology physicians, pediatric and neonatology physicians, oncology pharmacists and the other healthcare professionals directly involved in the chemotherapy of neonates and infants.

Contents: 1. Introduction -- 2. Protocols Used in Chemotherapy Treatment of Neonates and Infants -- 3. Pharmacokinetics and Pharmacodynamics of Chemotherapy Drugs in Neonates and Infants -- 4. Peculiarities of Most Commonly Used Chemotherapy Drugs in Neonates and Infants -- 5. Adjuvant Drugs Used in Chemotherapy for Neonates and Infants -- 6. Drug Interactions in Neonates and Infants -- 7. Toxicity -- 8. Tumor Lysis in Neonates and Infants -- 9. Chemotherapy in Neonates and Infants with Cancer and Other Congenital Diseases: Down Syndrome and HIV -- 10. Stem Cell Transplantation in Neonates and Infants.